intranasally with a lethal dose of A/PR/8/34. Sequence analysis of the NP CTL epitope of AIPR/8/34 challenge virus obtained from lungs after 8 days of replication in ESNP(147-155)-VAC-immunized mice showed identity with that of the input virus, demonstrating that an escape mutant had not emerged during replication in vivo.
Thus, in contrast to adoptively transferred CTLs, pulmonary NP-specific CTLs induced by recombinant vaccinia virus immunization do not have protective in vivo antiviral activity against influenza virus infection.
Cytotoxic T lymphocytes (CTLs) appear to play an important role in host immune response, limiting replication and accelerating clearance of many different viruses. With respiratory viruses such as influenza A virus, adoptive transfer of murine primary or restimulated immune spleen cells causes a significant reduction of infectious virus levels in the lungs of mice and prevents death from intranasal (i.n.) challenge with a lethal dose of influenza A virus (1, 42) . The specific effectorcell subset was found to be the CD8+ major histocompatibility complex class I-restricted antiviral CTLs, and the nucleoprotein (NP) was identified as the dominant viral determinant recognized by these influenza virus-specific (38) and influenza virus subtype-cross-reactive CTLs (9, 43) . Since NP is conserved among different strains of influenza A virus, it has been suggested that an NP-based vaccine may protect against different influenza A virus subtypes (13) . Indeed, adoptive transfer of NP-specific CTL clones confers cross-protection from lethal challenge with heterologous influenza A viruses (36) .
CTLs specific for NS1 and hemagglutinin (HA) epitopes also have protective effects when adoptively transferred to mice (20, 21) . In previous experiments in which protection was observed, polyclonal or clonal CD8+-activated CTLs derived from spleens of immunized mice were expanded in vitro by restimulation with antigen and were then transferred intravenously to naive mice, often simultaneously with recombinant interleukin-2 (24, 25, 36, 41) . A positive correlation of CTL cytolytic activity in vitro with the clearance rate of virus in the lungs of influenza virus-infected mice has been observed (26) . However, studies in which immunization in vivo was used to induce CTL activity have generally resulted in poor protective immunity (5, 6, 14, 35) even after hyperimmunization of animals (2, 4, 13, 40) . Therefore, CTLs naturally induced by infection in vivo, in contrast to results from adoptive transfer experiments, appear to be less effective in their antiviral function in vivo, and this was thought to be due to factors such as insufficient activation and poor recruitment of effector cells to the site of the virus infection.
CD8+ T cells recognize a peptide in association with major histocompatibility complex class I molecules through the T-cell receptor (37) , and such peptides may be derived from two different pathways of protein processing. In the major pathway, transporter proteins convey peptides produced in the cytosol into the endoplasmic reticulum (28) . Alternatively, NH2-terminal signal leader sequences adjacent to CTL epitopes can bypass transporter proteins, presumably by posttranslational transit through the protein-conducting channel, normally used for signal recognition particle-mediated export. Once inside the endoplasmic reticulum, signal peptidase presumably liberates the peptide from the leader (17 (Boehringer) . Reverse transcription was carried out with the influenza A virus NP-specific primer, nucleotides 71 to 91 (5'-CTTACGAACAGATGGAGACTG -3'), and reverse transcriptase (AMV, Life Sciences Inc., St. Petersburg, Fla.). A 620-bp fragment of the synthesized NP cDNA was amplified by PCR using the above primer and a reverse NP primer, nucleotides 671 to 691 (5'-TTGY'ITf TCGTCCATTCTCAC-3'). The PCR product was purified by using spun columns, and the sequence across the CTL epitope region was analyzed with the NP oligonucleotide, nucleotides 401 to 415 (5'-TCTGGCGCCAAGCTA-3') by Sequenase version 2.0 (U.S. Biochemicals, Cleveland, Ohio) as described previously (22) .
RESULTS
Induction of primary pulmonary CTLs by immunization of mice with vaccinia virus recombinants. Peak pulmonary CTL activity to vaccinia virus and to expressed proteins occurs at about day 6 PI (7) . Mice infected with the influenza virusvaccinia virus recombinants were therefore assessed for primary pulmonary CTL activity at this time point. BALB/c mice were inoculated with influenza virus A/PR/8/34-vaccinia virus recombinants simultaneously by the i.n. and i.p. routes since this immunization regimen induced CD8+ CTL-mediated resistance to another respiratory virus, namely respiratory syncytial virus (RSV) (19) . A high dose of ESNP(147-155)-VAC (107 PFU per mouse), but not 10-fold less (data not shown), induced primary CTL activity against NP peptide (147-155) and A/PR/8/34 virus as measured in the in vitro 5"Cr-release assay (Fig. 1) . The ESNP(147-155)-VAC and NP(Met 147-155)-VAC induced a high level of primary pulmonary CTL activity to NP peptide-pulsed targets (Fig. 1) . Primary CTL responses to A/PR/8/34, and to a lesser extent to NP peptidepulsed targets, were detected in mice infected i.n. with A/PR/ 8/34 virus (Fig. 1, experiment 2 We next studied whether immunization with minigene NPvaccinia virus recombinant virus would accelerate the clearance of the influenza challenge virus from the lungs. BALB/c mice were immunized with the vaccinia virus recombinants and challenged i.n. with A/PR/8/34 on day 6 as described above, and the kinetics of virus replication in the lungs was determined from day 4 to day 10 postchallenge (Fig. 3) (Fig. 4) . Six days after immumzation, A/PR/8/34 virus was given i.n. at a dose of 1i0 TCID50, (which represents approximately 1 50% lethal dose (Fig. 4A and B 
DISCUSSION
In previous studies, we and others have found that one or two doses of NP-VAC did not significantly decrease the replication of A/PR/8/34 virus in the lungs of mice of several major histocompatibility complex haplotypes, including H-2*, H-2k, and H-2d (5, 6, 14, 35 This finding was surprising to us, since primary pulmonary CTL effectors induced by immunization with M2RsV-VAC readily decreased replication of RSV challenge virus administered 6 days after immunization (19) . Although protection against RSV was short-lived, resistance correlated with the level of primary pulmonary CTL activity mediated by CD8+ T cells (19) . Differences in the virulence levels of these viruses could contribute to the observed differences in efficacy, since RSV infection is only semipermissive in mice, while influenza A/PR/8/34 virus infection can be lethal.
CTL activity induced by immunization with vaccinia virus recombinants can induce resistance to certain virus infections. The immediate-early nonstructural antigen, pp89, of murine cytomegalovirus expressed by vaccinia virus recombinant induces CD8+ CTLs which protect mice from lethal murine cytomegalovirus disease (8, 18) . A spectrum of CTL activities to NP of lymphocytic choriomeningitis virus (LCMV) and protective efficacies has been observed in NPLCMV-VACinfected mouse strains (16) . NP-CTL activity was not detected in B10.BR (H-2k) mice, a low and transient NP-CTL activity associated with partial resistance was seen in B10.D2 (H-2") mice, and a high and longer-lasting NP-CTL activity associated with strong resistance in C57BL/6 (H-2b) mice was found.
Importantly, minigenes of CTL epitopes of LCMV NP and glycoprotein GP coexpressed by vaccinia virus can induce a protective CTL response in certain mouse strains (31, 32 Several immunological mechanisms could underlie the seemingly contradictive evidence of the protective effects of influenza virus-specific CTLs generated in vivo and of those restimulated in vitro. First, the number of NP-specific CTLs stimulated in vivo by immunization and present at the tissue site of challenge virus replication may not be sufficient to restrict virus replication, whereas larger numbers of adoptively transferred CTLs would traffic to the lung and accumulate in the lung parenchyma, bronchial mucosa, epithelium, and airway lumen (27) . We have found a total of approximately 107 lymphocytes present in the lungs of ESNP(147-155)-VACinfected BALB/c mice at day 6 PI, and of this population only a fraction will be CMLs specific for NP. In cell transfer experiments, larger numbers of NP-specific T cells are transferred (up to 108 cells). The minimum number of adoptively transferred primary immune T cells (5 x 107) was found to be higher than that for secondary polyclonal T cells (2 x 107) for a 100% survival rate of CBA mice to challenge influenza A/WSN virus infection (41) . Second, the inherent in vivo antiviral activities of CTL populations may differ depending on whether the CTLs are restimulated in vitro. For example, it is possible that CD8+ T cells with high densities and/or affinities of the T-cell receptors specific for the NP epitope might be selectively amplified during in vitro restimulation. Such CTLs may have stronger in vivo antiviral activities than CTLs induced by a single immunization of NP in vivo. Third, since the avidities of the T-cell receptors for NP can be affected by accessory and/or adhesion molecular interactions (34) (29) . It is unknown whether the diminished NP-specific CTL protective immunity seen in our influenza virus-challenged mice is due to exhaustion of CTLs driven by NP antigen, but this remains a possibility. However, we think this is unlikely to be a major factor, since a low dose of challenge virus was used in the present study and exhaustion with LCMV required high doses of virus. Importantly, the present study in which the in vitro cytotoxic activity and in vivo efficacy of CD8+ CTLs have been found to be dissociated provides a system in which the mediators of antiviral resistance in vivo can be further defined.
The potential usefulness of the inclusion of CTL epitopes in vaccines for respiratory virus infections such as influenza A virus has been examined in the present study. Our findings, in the context of those of others (40) , emphasize the importance of a complete analysis of the immunogenicity and protective efficacy of a CTL epitope before its inclusion in a vaccine is validated. First, the proposed CTL epitope or set of CTL epitopes must be recognized by a high percentage of the target human population. Second, the immunogenicity of the CTL epitope in the vaccinees should be readily measurable by in vitro assays. Third, and most importantly, the CTL response induced by immunization with the virus vaccine must adequately protect the host from disease caused by the wild-type virus and this protection should be long lasting. Clearly, the present study demonstrates that the presence of in vitro cytotoxic activity in vaccinated animals is insufficient to predict in vivo efficacy of the vaccine for influenza virus and this underscores the need for the efficacy studies in vivo. Furthermore, the NP-specific CTL epitope examined in the present study, or another CTL epitope with comparable in vivo properties, would not appear to be a useful component of an influenza A virus vaccine.
